The FDA database lists a supplement dated 21 September 2026 to a generic acetazolamide application held by Indicus Pharma (ANDA090779). The record names only the applicant, product and application number. It does not state what was changed, whether labelling was revised, or whether any safety issue is involved.
Supplements to generic applications cover many routine matters. This entry should not alter use of oral acetazolamide for glaucoma or other indications. Prescribers can check the current product label if their supplier notifies a change.
- No change to prescribing follows from this listing alone.
- The record does not describe the content of the supplement.
- Check the current label for the product you dispense if your pharmacy flags an update.
Why it matters
It is a prompt to watch for label updates, not evidence of a new risk.
Don't overread it
A supplement to a generic application is administrative information, not a safety communication or a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free